Publications by authors named "David Dearnaley"

Claim this Profile
M
Moderate hypofractionated radiotherapy for localised prostate cancer: A new standard of care.
David Dearnaley

Cancer Radiother· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Silke Gillessen, Laura Murphy, Nicholas D James, Ashwin Sachdeva, Omar El-Taji, David P Dearnaley

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation-induced lymphocyte apoptosis and chromosomic aberrations for prediction of toxicities in patients undergoing radical radiotherapy for breast or prostate cancers.
David Azria, Joanne S Haviland, Muriel Brengues, Clare Griffin, Jayne Moquet, David P Dearnaley

Br J Radiol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium.
Amar U Kishan, Yilun Sun, Alison C Tree, Emma Hall, David Dearnaley

Lancet Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials.
John Nikitas, Parsa Jamshidian, Alison C Tree, Emma Hall, David Dearnaley

Lancet Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bladder Tumor-Focused Adaptive Radiation Therapy: Clinical Outcomes of a Phase I Dose Escalation Study.
Shaista Hafeez, Karole Warren-Oseni, Kelly Jones, Kabir Mohammed, Amir El-Ghzal, David Dearnaley

Int J Radiat Oncol Biol Phys· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer.
Javier Fernandez-Mateos, George D Cresswell, Nicholas Trahearn, Katharine Webb, Chirine Sakr, David Dearnaley

Nat Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to J.A. Garcia et al.
Susan Halabi, Siyuan Guo, Akash Roy, Larysa E Rydzewska, Peter Godolphin, David P Dearnaley

J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weekly ultra-hypofractionated radiotherapy in localised prostate cancer.
Nora Sundahl, Douglas Brand, Chris Parker, David Dearnaley, Alison Tree

Clin Transl Radiat Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials.
Lucia Kwak, Praful Ravi, John G Armstrong, Veronique Beckendorf, Joseph L Chin, David P Dearnaley

J Clin Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Susan Halabi, Akash Roy, Larysa Rydzewska, Siyuan Guo, Peter Godolphin, David P Dearnaley

J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Society of Urological Pathology (ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial.
David Dearnaley, Clare L Griffin, Pedro Silva, Anna Wilkins, Christine Stuttle

BJU Int· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gastrointestinal Toxicity Prediction Not Influenced by Rectal Contour or Dose-Volume Histogram Definition.
Douglas H Brand, Sarah C Brüningk, Anna Wilkins, Olivia Naismith, Annie Gao, David P Dearnaley

Int J Radiat Oncol Biol Phys· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.
Soumyajit Roy, Tahmineh Romero, Jeff M Michalski, Felix Y Feng, Jason A Efstathiou, David P Dearnaley

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types.
Elnaz Naderi, Miguel E Aguado-Barrera, Line M H Schack, Leila Dorling, Tim Rattay, David P Dearnaley

JNCI Cancer Spectr· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Personalized Clinical Dynamic Prediction Model to Characterize Prognosis for Patients With Localized Prostate Cancer: Analysis of the CHHiP Phase 3 Trial.
Harry Parr, Nuria Porta, Alison C Tree, David Dearnaley, Emma Hall

Int J Radiat Oncol Biol Phys· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Gerhardt Attard, Laura Murphy, Noel W Clarke, Ashwin Sachdeva, Craig Jones, David P Dearnaley

Lancet Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on "Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients".
Miguel R Ferreira, Jervoise N Andreyev, Linda Wedlake, David P Dearnaley

Br J Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Fraction Size Sensitivity of Late Genitourinary Toxicity: Analysis of Alpha/Beta (α/β) Ratios in the CHHiP Trial.
Douglas H Brand, Sarah C Brüningk, Anna Wilkins, Olivia Naismith, Annie Gao, David P Dearnaley

Int J Radiat Oncol Biol Phys· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE Trial.
Alison C Tree, Laura Satchwell, Emma Alexander, Irena Blasiak-Wal, Nandita M deSouza, David Dearnaley

Int J Radiat Oncol Biol Phys· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.
Ting Martin Ma, Yilun Sun, Shawn Malone, Mack Roach, David Dearnaley

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation.
Anna Wilkins, Barry Gusterson, Holly Tovey, Clare Griffin, Christine Stuttle, David Dearnaley

EBioMedicine· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).
Ting Martin Ma, Fang-I Chu, Howard Sandler, Felix Y Feng, Jason A Efstathiou, David P Dearnaley

Eur Urol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
Nicholas D James, Fiona C Ingleby, Noel W Clarke, Claire L Amos, Gerhardt Attard, David P Dearnaley

JNCI Cancer Spectr· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
Chris C Parker, Nicholas D James, Christopher D Brawley, Noel W Clarke, Adnan Ali, David P Dearnaley

PLoS Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis